How many insider trades does FilingIQ track for PRQR?

FilingIQ tracks 3 Form 4 insider transactions for PRQR (ProQR Therapeutics N.V.), covering filings from Jun 2, 2026 onwards. 3 of those were filed in the last 90 days.

Are PRQR insiders net buyers or net sellers?

Across the full Form 4 history for PRQR, 1 transactions (33%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does PRQR insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is PRQR in?

ProQR Therapeutics N.V. (PRQR) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $154.88M.

PRQR insider trading

NasdaqCM Healthcare

ProQR Therapeutics N.V. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

33% / 0%

Market cap

$154.88M

About ProQR Therapeutics N.V.

ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic diseases. The company also develops AX-2402, which targets methyl CpG binding protein 2 mutations for Rett syndrome; AX-2911, which targets PNPLA3 for metabolic dysfunction-associated steatohepatitis; and AX-1412, which targets the B4GALT1 gene for cardiovascular diseases. It has a research and collaboration agreement with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

Company website: www.proqr.com

PRQR insider activity at a glance

FilingIQ has scored 3 insider transactions for PRQR since Jun 2, 2026. The most recent filing in our index is dated Jun 26, 2026.

Across the full history, 1 open-market purchases and 0 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on PRQR insider trades is 57.0/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live PRQR trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 274

Apellis Pharmaceuticals, Inc.

KYMR 234

Kymera Therapeutics, Inc.

GH 194

Guardant Health, Inc.

Frequently asked

How many insider trades does FilingIQ track for PRQR?: FilingIQ tracks 3 Form 4 insider transactions for PRQR (ProQR Therapeutics N.V.), covering filings from Jun 2, 2026 onwards. 3 of those were filed in the last 90 days.
Are PRQR insiders net buyers or net sellers?: Across the full Form 4 history for PRQR, 1 transactions (33%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does PRQR insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is PRQR in?: ProQR Therapeutics N.V. (PRQR) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $154.88M.

Methodology & sources

Every PRQR insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.